Akebia SVP Rucci reports initial share, option holdings
Akebia Therapeutics executive Carolyn M. Rucci, SVP and Chief Legal Officer, filed an initial ownership report showing her equity position in the company.
Rhea-AI Filing Summary
Akebia Therapeutics executive Carolyn M. Rucci, SVP and Chief Legal Officer, filed an initial ownership report showing her equity position in the company. She reports beneficial ownership of multiple blocks of Akebia common stock, including 171,816 shares held directly and additional shares linked to restricted stock unit grants.
The filing also lists several employee stock options to buy Akebia common stock, with exercise prices ranging from $0.63 to $2.88 per share and expiration dates between 2031 and 2035. These options generally vest over four years, with 25% vesting after one year and the remainder in equal quarterly installments, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Rucci Carolyn M.
Role
SVP, Chief Legal Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 718,500 contracts (Direct);
Common Stock — 468,150 shares (Direct)
Footnotes (5)
- F1. The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. All of the restricted stock units will vest on January 31, 2026, subject to the reporting person's continued service with the Issuer on such vesting date.
- F2. The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
- F3. The options were granted by the Issuer as an inducement material to the reporting person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
- F4. The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
- F5. The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Akebia Therapeutics (AKBA) Form 3 for Carolyn M. Rucci show?
The Form 3 shows Carolyn M. Rucci’s initial beneficial ownership of Akebia common stock and employee stock options. It details several common stock positions and option grants, including holdings tied to the company’s 2014 and 2023 equity incentive plans with specified vesting schedules.
What stock option grants for Akebia (AKBA) are disclosed for Carolyn M. Rucci?
The filing lists several employee stock options to buy Akebia common stock: 61,000 shares at $2.88, 27,900 at $2.16, 165,600 at $0.63, 224,000 at $1.68, and 240,000 at $2.24, each with specified future expiration dates between 2031 and 2035.
How do Carolyn M. Rucci’s Akebia (AKBA) equity awards vest according to the Form 3?
Restricted stock units under the 2014 plan vest fully on January 31, 2026, while units under the 2023 plan vest one-third on each of the first three anniversaries of the grant date. Most option grants vest 25% after one year, then quarterly over the following three years.
What is the inducement stock option grant disclosed for Akebia (AKBA) SVP Carolyn M. Rucci?
One option grant was awarded as an inducement material to her employment under Nasdaq Listing Rule 5635(c)(4). This grant vests over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal quarterly installments, subject to continued service.
Does the Akebia (AKBA) Form 3 for Carolyn M. Rucci report any stock sales or purchases?
The Form 3 functions as an initial ownership report and lists existing common stock and option holdings. It describes restricted stock units and stock options with future vesting and expiration terms rather than recording new open-market stock sales or purchases by Carolyn M. Rucci.
AI-generated analysis. How Rhea-AI works. Not financial advice.
